(Q44564584)

English

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

scientific article published in September 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

based on heuristic

inferred from title

Hagop Kantarjian

15

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

10

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jorge Eduardo Cortes

4

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

5

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2

object named as

Francis Giles

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Guillermo Garcia-Manero

11

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Michael Andreeff

8

object named as

Michael Andreeff

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Steven M Kornblau

9

object named as

Steven Kornblau

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

6

object named as

Jianqin Shan

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

13

object named as

Susie Mallard

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Deborah Thomas

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Kevin White

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Emil Freireich

14

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

888-893

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine: history, current research, and future direction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Disruption of the long-range GPIIIa Cys(5)-Cys(435) disulfide bond results in the production of constitutively active GPIIb-IIIa (alpha(IIb)beta(3)) integrin complexes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11620

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11620

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44564584&oldid=2218887985"